{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:21:27Z","timestamp":1793578887395,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":70,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-026-02406-y","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T09:35:08Z","timestamp":1781688908000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term safety and continued clinical benefit of erenumab 70\u00a0mg in Asian patients with chronic migraine: an open-label extension of the phase 3 DRAGON study"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8933-088X","authenticated-orcid":false,"given":"Shengyuan","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1053-4682","authenticated-orcid":false,"given":"Byung-Kun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0598-5772","authenticated-orcid":false,"given":"Hebo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6302-8332","authenticated-orcid":false,"given":"Jiying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partha","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremie","family":"Lincy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeniya","family":"Reshetnyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1410-5615","authenticated-orcid":false,"given":"Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Leclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5179-5358","authenticated-orcid":false,"given":"Shuu-Jiun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"2406_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z (2020) Lifting The Burden: the Global Campaign against, Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain 21:137","journal-title":"J Headache Pain"},{"key":"2406_CR2","doi-asserted-by":"crossref","unstructured":"G.B.D.H.C.E.a. yonkkang@gmail.com, T. Wijeratne, J. Oh, S. Kim, Y. Yim, M.S. Kim,J.I. Shin, Y.S. Oh, R. Jung, Y.S. Kim, L. Smith, H. Aalruz, R. Abd-Rabu, D.M. Abdulah,R.G. Aboagye, M. Abolmaali, D. Abtahi, A. Abualhasan, R.A. Adedoyin, Q.E.S. Adnani,F. Afrashteh, N. Aggarwal, D. Ahmad, A. Ahmadi, N.S. Ahmadi, A.M. Ahmadzade, S.A.Ahmed, S. Al Awaidy, S. Alabbad, M.M. Alajlani, Y. Al-Ajlouni, M.U. Ali, S.S. Ali,W. Ali, J.U. Almazan, N.Z. Alshahrani, A. Altaf, M. Al-Wardat, K.H. Alzoubi, S. Amiri,H. Amu, G.A. Amusa, D.B. Anderson, S. Anwar, D. Areda, M. Asghari-Jafarabadi, S. Ashina,J. Ashraf, T. Ashraf, A. Azargoonjahromi, Y. Bahurupi, A.A. Baig, S. Bandyopadhyay,M. Bardhan, H.J. Barqawi, A. Bashiri, M.M. Bastan, M. Bemanalizadeh, I.M. Bensenor,A.Y.Y. Berhie, A.S. Bhagavathula, S. Bhaskar, V. Bhat, G.K. Bhatti, J.S. Bhatti, C.Bilgin, A. Biswas, B. Bizzozero-Peroni, Y. Bustanji, L.A. Camera, E. Caronna, A.F.Carvalho, S. Chakraborty, P.R. Ching, N. Christodoulou, D.T. Chu, H. Chu, N. Cruz-Martins,O. Dadras, X. Dai, E. D\u2019Amico, A.H. Darwish, S. Deekonda, V.G.C. Devanbu, S.D. Dharmaratne,A. Dima, T.E. Dinkayehu, H. Do, P.N. Doku, O.P. Doshi, R. E\u2019Mar A, N. Eissazade, C.Eltaha, A. Fahim, J. Fares, M. Farjoud Kouhanjani, A. Faro, P. Fazeli, S.M. Fereshtehnejad,P. Ferrara, N. Ferreira, F. Fischer, A. Fornari, M. Gajdacs, M.W. Gebregergis, D.J.Ghadimi, A. Ghaffari Jolfayi, E.V. Gnedovskaya, M. Golechha, E. Gomez Figueroa, M.H.Hashempur, M.S. Hasnain, A. Hassan, N. Hassan, M.S. Hassan Zadeh Tabatabaei, M.I.Hegazy, G. Heidari, B. Helfer, M.M. Hossain, M. Househ, C. Hu, I. Iavicoli, O.S. Ilesanmi,I.M. Ilic, M.F. Ilyas, S. Ilyasu, N.E. Ismail, A. Jafari-Khounigh, H. Jahrami, M.D.Janodia, R.D. Jayasinghe, B.M. Jeswani, J.B. Jonas, N. Joseph, R. Kalani, M.A.B. Khan,S. Khateri, M.N. Khatib, H.R. Khayat Kashani, F.F. Khidri, M. Khormali, S. Khosravi,Y.J. Kim, F. Kompani, K. Kostev, K. Krishan, B. Krishnan, B.K. Defo, M. Kuddus, M.Kulimbet, R. Kumar, V. Kumar, V. Kyto, S. Lasrado, S.W. Lee, J. Lenzi, M. Leonardi,G. Lucchetti, A. Lugo, I.F. Makhdoom, A. Mallahzadeh, V. Mansouri, R.R. Marzo, Y.Mathangasinghe, M. Mayeli, A. Mehmood, A. Meretoja, T. Mestrovic, S. Mettananda, G.Minervini, A. Mishra, P. Mithra, K.A.H. Mohamed Ahmed, I. Mohammadzadeh, S. Mohammed,L. Monasta, S.D. Morrison, A. Nabavi, Z.S. Natto, J. Nauman, L. Nieddu, F. Nugen,A.T. Olagunju, A.B. Oliveira, W.S. Oliveira, H.A. Omar, G.L. Omer, N. Otstavnov, A.M.P, L.D. Panos, R.R. Parikh, S. Patil, A. Patra, P. Pedersini, U. Pensato, P. Peprah,M.F.P. Peres, M.A. Piradov, P. Pozo-Rosich, J. Pradhan, S. Prakash, A. Prashant, J.Puvvula, A. Rafiei, A. Raggi, A.M. Rahmani, M.M. Ramadan, D. Rathish, I. Rautalin,S. Rawaf, M. Rezaeian, D. Rezazadeh Eidgahi, T.G. Rhee, P. Roy, A. Saad Eddin, C.J.Sabet, B.A. Saddik, E. Sadeghi, U. Saeed, F. Saheb Sharif-Askari, N. Saheb Sharif-Askari,P.M. Sahoo, S. Salimi, A.M. Samy, J. Saulam, M. Sawhney, Y.C. Senol, S. Senthilkumaran,Y. Sethi, H. Seyedmirzaei, M. Shafie, A. Shamsi, A. Sharifan, H.S. Shehata, R.R. Shenoy,F. Shokraneh, J.K. Sidhu, B. Singh, H. Singh, J.A. Singh, S. Singh, A.A. Skryabina,F. Sobia, B.S. Srichawla, V. Suresh, C.K. Swain, Y.S. T, P. Tabaee Damavandi, C. Tabche,M. Tabish, M. Tanwar, M.H. Temsah, M. Teramoto, N.M. Tran, T.H. Tran, A. Tsatsakis,A.J. Udoakang, J.S. Usman, H. Uzuncibuk, J. Van den Eynde, T.J. Vasankari, N. Venketasubramanian,J.H. Villafane, L. Wang, X. Wang, Y.P. Wang, T. Wiangkham, A.S. Winkler, A.M. Wollie,Z. Xiao, Y.E.E. Yismaw, A. Yousuf, Z. Zhao, M. Zielinska, M.K. Chu, T.J. Song, D.K.Yon, V.L. Feigin (2025). Global, regional, and national burden of headache disorders, 1990\u20132021,with forecasts to 2050: a global burden of disease study 2021, Cell Rep Med, 6;102348","DOI":"10.1016\/j.xcrm.2025.102348"},{"key":"2406_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s10194-025-01990-9","volume":"26","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Yi Y, Zhou H, Pang Q, Wang J (2025) The burden of migraine and tension-type headache in Asia from 1990 to 2021. J Headache Pain 26:49","journal-title":"J Headache Pain"},{"key":"2406_CR4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11916-011-0233-z","volume":"16","author":"Z Katsarava","year":"2012","unstructured":"Katsarava Z, Buse DC, Manack AN, Lipton RB (2012) Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep 16:86\u201392","journal-title":"Curr Pain Headache Rep"},{"key":"2406_CR5","first-page":"1","volume":"38","author":"IHS Headache Classification Committee o","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1\u2013211","journal-title":"Cephalalgia"},{"key":"2406_CR6","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB (2015) Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 35:478\u2013488","journal-title":"Cephalalgia"},{"key":"2406_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s10194-020-01117-2","volume":"21","author":"S Yu","year":"2020","unstructured":"Yu S, Zhang Y, Yao Y, Cao H (2020) Migraine treatment and healthcare costs: retrospective analysis of the China Health Insurance Research Association (CHIRA) database. J Headache Pain 21:53","journal-title":"J Headache Pain"},{"key":"2406_CR8","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P, Hansen RN, Devine EB (2017) Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis. Cephalalgia 37:470\u2013485","journal-title":"Cephalalgia"},{"key":"2406_CR9","doi-asserted-by":"crossref","unstructured":"Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Lenz R, Wang Y, Cheng S, Hirama T, Mikol DD (2019) A randomized phase 2 study of erenumab for the prevention of episodic migraine in Japanese Adults. Headache. 59;1731\u20131742","DOI":"10.1111\/head.13652"},{"key":"2406_CR10","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/head.14169","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Kim BK, Igarashi H, Hirata K, Takeshima T, Ning X, Shima T, Ishida M, Iba K, Kondo H, Koga N (2021) Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61:1092\u20131101","journal-title":"Headache"},{"key":"2406_CR11","doi-asserted-by":"crossref","unstructured":"Hirata K, Komori M, Ueda K, Zagar AJ, Kim Y, Jaffe DH, Matsumori Y, Takeshima T (2023) Outcomes and factors associated with insufficient effectiveness of acute treatments of migraine in japan: results of the observational survey of the epidemiology, treatment, and care of MigrainE (OVERCOME [Japan]) Study. Drugs Real World Outcomes. 10;415\u2013428","DOI":"10.1007\/s40801-023-00368-0"},{"key":"2406_CR12","doi-asserted-by":"crossref","unstructured":"Reuter U (2018) A Review of monoclonal antibody therapies and other preventative treatments in migraine, Headache. 58(1):48\u201359","DOI":"10.1111\/head.13302"},{"key":"2406_CR13","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/0333102418821662","volume":"39","author":"DW Dodick","year":"2019","unstructured":"Dodick DW (2019) CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications. Cephalalgia 39:445\u2013458","journal-title":"Cephalalgia"},{"key":"2406_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1124\/jpet.115.227793","volume":"356","author":"L Shi","year":"2016","unstructured":"Shi L, Lehto SG, Zhu DX, Sun H, Zhang J, Smith BP, Immke DC, Wild KD, Xu C (2016) Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor. J Pharmacol Exp Ther 356:223\u2013231","journal-title":"J Pharmacol Exp Ther"},{"key":"2406_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, Brandes JL, Dolezil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16:425\u2013434","journal-title":"Lancet Neurol"},{"key":"2406_CR16","unstructured":"A.U.S (2021) p. information"},{"key":"2406_CR17","unstructured":"A.S.o.p. characteristics"},{"key":"2406_CR18","unstructured":"N.P. release., Novartis marks a new era for migraine patients with the EU approval of Aimovig\u00ae, a first-of-its-kind treatment specifically designed for migraine prevention"},{"key":"2406_CR19","unstructured":"Amgen Amgen announces approval of Aimovig\u00ae (Erenumab) in Japan for the suppression of onset of migraine attacks in adults"},{"key":"2406_CR20","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s10194-022-01514-9","volume":"23","author":"S Yu","year":"2022","unstructured":"Yu S, Kim BK, Wang H, Zhou J, Wan Q, Yu T, Lian Y, Arkuszewski M, Ecochard L, Wen S, Yin F, Li Z, Su W, Wang SJ (2022) A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study. J Headache Pain 23:146","journal-title":"J Headache Pain"},{"key":"2406_CR21","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/d41573-024-00034-2","volume":"23","author":"LQ Zhi","year":"2024","unstructured":"Zhi LQ, Shao X (2024) Approvals by the China NMPA in 2023. Nat Rev Drug Discov 23:164\u2013165","journal-title":"Nat Rev Drug Discov"},{"key":"2406_CR22","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1177\/03331024211024160","volume":"41","author":"SJ Wang","year":"2021","unstructured":"Wang SJ, Roxas AA Jr., Saravia B, Kim BK, Chowdhury D, Riachi N, Tai MS, Tanprawate S, Ngoc TT, Zhao YJ, Mikol DD, Pandhi S, Wen S, Mondal S, Tenenbaum N, Hours-Zesiger P (2021) Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study. Cephalalgia 41:1285\u20131297","journal-title":"Cephalalgia"},{"key":"2406_CR23","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1177\/0333102419888222","volume":"39","author":"M Ashina","year":"2019","unstructured":"Ashina M, Kudrow D, Reuter U, Dolezil D, Silberstein S, Tepper SJ, Xue F, Picard H, Zhang F, Wang A, Zhou Y, Hong F, Klatt J, Mikol DD (2019) Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions. Cephalalgia 39:1798\u20131808","journal-title":"Cephalalgia"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-026-02406-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02406-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02406-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T02:00:21Z","timestamp":1787709621000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10194-026-02406-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2406"],"URL":"https:\/\/doi.org\/10.1186\/s10194-026-02406-y","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol and all amendments were reviewed by the Independent Ethics Committee (IEC) or Institutional Review Board (IRB) at each study centre. The study was conducted according to International Council for Harmonisation E6 guideline for good clinical practice guideline for Good Clinical Practice (GCP) and the ethical principles laid down in the Declaration of Helsinki. All participants provided written informed consent before undergoing any study-specific procedures.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Statistical analysis was conducted by Jeremie Lincy (Novartis Pharma AG, Basel, Switzerland) and Evgeniya Reshetnyak (Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA).","order":2,"name":"Ethics","label":"Statistical analysis","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shengyuan Yu, Hebo Wang, and Jiying Zhou declare that there is no conflict of interest. Shuu-Jiun Wang has received personal compensation for serving on a Scientific Advisory board for Eli-Lilly and Novartis. He has received personal compensation for serving on as a speaker or moderator for AbbVie, Biogen, Eisai and Pfizer, Taiwan. The institution of Prof. Wang has received research support from Brain Research Center, National Yang-Ming University from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan, Eli-Lilly and Novartis. Byung-Kun Kim has received personal compensation for serving on a Scientific Advisory board for Lundbeck Korea and Novartis. He has received personal compensation for serving on as a speaker or moderator for Allergan Korea, Lilly Korea, Teva Korea, GSK Korea, Lundbeck Korea and SK pharm. Partha Banerjee, Jeremie Lincy, Evgeniya Reshetnyak, and Denise Leclair are employees of and hold stocks in Novartis. Zheng Li is an employee of China Novartis Institutes for Biomedical Research Co Ltd., Shanghai, China.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"217"}}